PTPRC and neoplasm: This approach includes positive selection with antibodies against tumor-associated antigens such as EpCAM, CKs, mucin-1, human epidermal growth factor receptor 2, or epithelial growth factor receptor [50–52] and negative selection with antibodies against the common leukocyte antigen CD45 [53].